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In normal man, the serum phosphate concentration is
maintained within a narrow range, despite random and
spontaneous variations in phosphorus ingestion. On an
average diet in the United States, the intake of elemental
phosphorus approximates one gram per day. Of this
amount, about 30% is excreted through the gastrointestinal
tract and 70%, or about 700 mg/day, is excreted by the
kidneys. To effect this rate of excretion with a normal
glomerular filtration rate (GFR), some 15% of the filtered
load of phosphate must be excreted; the tubular reabsorp-
tion of phosphate (TRP) thus is equal to about 85% of the
filtered load. The absolute value for TRP will vary depend-
ing upon the amount of phosphate requiring excretion, and
the primary effector element in the control system which
governs phosphate homeostasis appears to be parathyroid
hormone (PTH). Most studies indicate that the modulation
of tubular reabsorption of phosphate takes place in the
proximal tubule [1—3], although some investigators have
presented evidence suggesting distal participation in phos-
phate reabsorption [4, 5].
In chronic renal disease, the control system responsible
for the maintenance of external phosphate balance is
perturbed progressively by virtue of the continuing loss of
excretory units. As GFR falls, an adaptation takes place in
phosphate excretion which is characterized by a progressive
decrease in TRP, and thus by an increase in the rate of
phosphaturia per residual nephron. This adaptation is suf-
ficiently precise to permit the maintenance of normal
serum phosphate concentrations on an unrestricted phos-
phorus intake until relatively late in the course of advancing
chronic renal disease. We have demonstrated that PTH
plays a key role in mediating the increasing rate of phos-
phate excretion per nephron, and that when PTH release
is suppressed, either by sustained elevation of the serum
calcium concentration or by surgical removal of the para-
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thyroid glands, the augmented degree of phosphaturia per
nephron is reversed [6—8]. The role of PTH in the regulation
of external phosphate balance in advancing renal disease
is particularly important during the decline of GFR from
normal to approximately 25% of normal. However, once
the blood concentration of PTH exceeds the level at which
maximal inhibition of the tubular reabsorption of phos-
phate is to be expected, other factors, including a rising
concentration of serum phosphate (and thus an increase in
the filtered load of phosphate per residual nephron) and
possibly factors that inhibit proximal tubular sodium
reabsorption, must contribute to the regulation of phos-
phate balance.
In examining the events which initiate the adaptation in
phosphate excretion in chronic renal disease, we recently
have focused attention on the role of the phosphate ion
per se. Although it is known that phosphate does not
itself affect the release of parathyroid hormone [9], a close
relationship exists between phosphate and calcium me-
tabolism, and changes in ionized calcium concentrations
clearly influence the rate of parathyroid hormone release
[10, 11]. The possibility thus exists that primary and
repetitive changes in phosphate excretion attendant upon
the loss of nephrons and the fall in GFR could lead to
closely coupled changes in the concentration of ionized
calcium in the serum. In normal volunteers, it recently has
been shown that an increase in serum phosphate con-
centration, induced by the administration of an oral phos-
phate load, is associated with a reciprocal change in ionized
calcium and a rise in the level of serum parathyroid hor-
mone [12].
The specific hypothesis which we have proposed for the
pathogenesis of secondary hyperparathyroidism is as fol-
lows [13]: During the evolution of chronic renal disease,
recurrent but transient periods of phosphate retention must
occur each time GFR falls, for there will be a temporary
decrease in phosphate excretion, and if the intake and
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Fig. 1. Hypothetical treatment for the pathogenesis of secondary
hyperparathyroidism in advancing chronic renal disease. (From
[13].)
absorption of phosphorus remain constant positive balance
must ensue. The phosphorus retention, even though it may
be very small in magnitude, will lead to an increase in
plasma phosphate concentration; and the latter, it is
proposed, will produce a reciprocal decrease in the serum
calcium concentration. The fall in ionized calcium would
be sensed by the parathyroid glands which respond by
increasing the rate of parathyroid hormone secretion.
Finally, the increase in the level of PTH in the blood per-
fusing the kidneys, will serve to diminish the rate of TRP
and thereby promote a greater rate of phosphaturia per
remaining nephron. Thus, total phosphate excretion will
rise and the serum phosphate concentration will return to
normal. The elevated PTH level will also serve to increase
the serum calcium concentration by the action of this
hormone on bone and the gastrointestinal tract. With each
phase of nephron destruction, the same cycle should
recur; therefore, the levels of PTH should increase pro-
gressively as the degree of renal insufficiency increases.
This hypothesis, which is depicted schematically in Fig. 1,
has been subjected to experimental examination in dogs
with progressive renal insufficiency [14].
Studies were performed on two groups of dogs. The first
group was fed a diet containing 1,200 mg of phosphorus
per day. The second group received a low phosphorus diet
containing less than 100 mg of phosphorus per day.
Control studies were performed with both kidneys intact;
then approximately 70 to 80% of the right kidney was in-
farcted by ligating most of the branches of the right renal
artery. After a period of seven to ten days, a second set of
studies was performed and a similar surgical procedure was
performed on the left kidney. One week to ten days later,
the third set of studies was performed. The left kidney was
then removed, leaving only the nephrons in the small
remnant kidney on the right side. The fourth set of studies
then was obtained. With this experimental approach, the
Fig. 2. The relationship between parathyroid hormone levels and
GFR in two groups of dogs. One group (closed circles) was
maintained on a diet containing 1,200mg of phosphorus per
day. The other group (open circles) was maintained on a diet
containing less than 100 mg of phosphorus per day. PTH is
expressed in microliter equivalents per ml. (From [14].)
GFR was reduced in graded steps from a mean of ap-
proximately 60 mI/mm to 40, 20, and then to roughly
10 mI/mm.
Fig. 2 depicts the levels of serum PTH in the two groups
of dogs. Those animals maintained on 1,200 mg of phos-
phorus per day developed progressive secondary hyperpara-
thyroidism. In contrast, the dogs fed the low phosphorus
intake exhibited no increase in PTH levels, despite the
development of advanced renal insufficiency. The results of
these experiments clearly demonstrate that, at least for the
duration of the studies, secondary hyperparathyroidism
can be prevented by phosphate deprivation as GFR falls
from normal to very low levels.
The effects of administering a single load of phosphorus
to a uremic dog in the low phosphorus intake group are
shown in Fig. 3. After baseline measurements were obtain-
ed, 600 mg of phosphorus were fed by gastric tube and
observations were continued for 5 hr. The plasma phos-
phate concentration rose by approximately 3 mg/100 ml.
The serum calcium fell reciprocally, reaching a minimum
value approximately I mg/tOO ml below the baseline values
three hours after the phosphorus load. The serum PTFI
level rose by six-fold and the TRP, which originally was
98 %, decreased in a remarkable fashion to zero at the end
of five hours. These data demonstrate in a dramatic form
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Fig. 3. The effect of a single oral dose of 600 mg of phosphorus 
on serum phosphorus, calcium, TRP and parathyroid hormone 
levels in a uremic dog maintained chronically on a low phosphorus 
diet. (From [14].) 
a sequence of events triggered by the addition of phos- 
phorus to body fluids in a setting wherein the phosphate 
control system seemed to be hyper-responsive. The apparent 
order of events was as follows: phosphorus ingestion-+ ele- 
vation of serum phosphate concentration* reciprocal fall 
in calcium concentration-+increase in serum PTH+in- 
hibition of TRP+increased phosphate excretion per 
nephron. The fall in the serum calcium concentration in 
this experiment presumably was attenuated by the marked 
rise in the serum PTH levels; for when the same load of 
phosphorus was administered to the same dog after a total 
thyroparathyroidectomy, the decrease in both total and 
ionized serum calcium concentrations was strikingly greater 
(Fig. 4). 
A role of phosphorus in the genesis of secondary hyper- 
parathyroidism thus seems clearly implicated. However, 
the use of a very low phosphorus diet to prevent the 
development of hyperparathyroidism in advancing renal 
disease would be impractical, clinically, since it would 
require either severe limitation of protein intake and/or the 
administration of large doses of phosphate binding gels, 
starting early in the course of renal disease. Moreover, if 
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Fig. 4. The effects of a single oral dose of 600 mg of phosphorus 
on total and ionized serum calcium concentrations in the same dog 
shown in Fig. 3 after total thyroparathyroidectomy. (SLATOPOLSKY 
E, et al: Proceedings of the 5th Internat. Congress of Nephrology, 
Mexico, 1972. In Press.) 
a low phosphorus diet were to be maintained for months 
to years, phosphorus depletion and demineralization of the 
skeleton might well occur. Under these circumstances, one 
would simply substitute one pathologic condition, osteo- 
malacia, for another, hyperparathyroidism. 
In the hope of developing a regimen with clinical ap- 
plicability and, simultaneously, to provide a more rigorous 
test of the validity of the hypothesis for the pathogenesis of 
secondary hyperparathyroidism, a different experimental 
protocol was devised [15]. If, during the evolution of renal 
failure, the load of phosphorus to be excreted by the kidneys 
could be decreased in proportion to the decrement in GFR, 
the adaptive increase in phosphate excretion per nephron 
would not be required and hyperparathyroidism should not 
occur. Specifically, if the transient periods of phosphorus 
retention were avoided, there would be no peaks in serum 
phosphorus concentration, no reciprocal changes in ionized 
calcium concentration, and parathyroid hormone levels 
should not rise progressively. A series of experiments, 
therefore, was performed on a group of dogs in which renal 
mass again was decreased in sequential steps, and, during 
the control phase, phosphorus intake was maintained at 
1,200 mg/day. However, each time the nephron population 
was reduced, GFR was remeasured and the phosphorus 
intake was decreased by the same percentage as the fall in 
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Fig. 5. The effects of "proportional reduction" of phosphorus
intake on the pathogenesis of secondary hyperparathyroidism.
(This figure was constructed from tabular data published in
reference [15].)
GFR. The results of "proportional reduction" of phos-
phorus are shown in Fig. 5. No change in the levels of
serum phosphorus or calcium were detected throughout
the period of study. More critically, the TRP never fell
below 85 %, and the serum concentration of PTH remained
normal even at the lowest levels of GFR.
During the evolution of chronic renal disease, if phos-
phorus intake remains constant, the maintenance of phos-
phorus balance and the simultaneous prevention of hyper-
phosphatemia until GFR falls to quite low values, occur
because fractional excretion of phosphorus increases pro-
gressively in the surviving nephrons. PTH seems to be the
main modulator of this adaptive increase. Unfortunately,
the "trade-off" for the adaptation may be the development
of metabolic bone disease [16]. The studies in which a low
phosphorus diet was employed in dogs with experimentally
induced renal insufficiency demonstrate that secondary
hyperparathyroidism can be prevented. However, this
regimen imposes the risk of phosphate depletion and
osteomalacia. On the other hand, the use of "proportional
reduction" of phosphorus in the diet should obviate the
need for an adaptive increase in phosphate excretion per
nephron without imposing the risk of phosphate depletion.
This approach to the prevention of secondary hyperpara-
thyroidism thus would seem to have clinical applicability.
After GFR is measured, phosphorus intake can readily be
tion.
In summary, we believe that a basis now exists for a
prospective approach to the prevention of secondary hyper-
parathyroidism, and probably other forms of metabolic
bone disease, in advancing chronic renal disease. To date,
controlled studies have been performed only on dogs with
experimental renal disease; however, preliminary results in
patients are encouraging and long-term clinical studies must
now be undertaken.
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reduced in the diet in proportion to the decrement in GER
if renal function is not too severely impaired. Preliminary
studies in patients with chronic renal failure and GFR as
low as 30 mI/mm, indicate that secondary hyperpara-
thyroidism can be reversed by diminishing dietary phos-
phorus intake. If the GFR is below 30 mI/mm, the task of
preparing a suitably low phosphorus diet becomes difficult.
However, phosphate binding agents, such as aluminum
carbonate gel or aluminum hydroxide gel, may be used in
order to diminish phosphorus absorption by the gastro-
E D
intestinal tract. It should be emphasised that the kidney is
the only organ responsible for the conversion of 25-hydroxy-
cholecalciferol to 1,25-dihydroxycholecalciferol [17, 18],
fl
the most potent metabolite of vitamin D. Patients with
severe renal disease are unable to form this important
metabolite; thus, "proportional reduction" of phosphorus
intake will not eliminate any increase in PTH release which
results from the development of vitamin D resistance; for
once the latter abnormality is of sufficient severity to
impair the enteric absorption of calcium, a separate
mechanism may exist for decreasing the serum ionized
calcium concentration, and thus for provoking secondary
hyperparathyroidism. If vitamin D resistance ultimately is
shown to contribute importantly to one or more of the
component parts of uremic osteodystrophy, it will become
essential to add one of the potent metabolites of vitamin D
to the therapeutic regimen. However, before this is done,
any preexisting hyperphosphatemia must be corrected in
order to prevent the development of metastatic calcifica-
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